High levels of ERRα expression are associated with a poor prognosis in breast cancer [21], while several reports have described ERRα as a predictive biomarker of response to endocrine therapy in the same setting [22, 23, 24]. The gene discussed is ESRRA; the disease is breast carcinoma.